Nuvalent, Inc. (NUVL): Price and Financial Metrics
NUVL Price/Volume Stats
| Current price | $84.22 | 52-week high | $113.51 |
| Prev. close | $84.64 | 52-week low | $61.79 |
| Day low | $82.81 | Volume | 1,114,200 |
| Day high | $87.32 | Avg. volume | 438,656 |
| 50-day MA | $93.35 | Dividend yield | N/A |
| 200-day MA | $82.44 | Market Cap | 5.98B |
NUVL Stock Price Chart Interactive Chart >
Nuvalent, Inc. (NUVL) Company Bio
Nuvalent, Inc., a preclinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor, designed to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors; and NVL-655, a brain-penetrant ALK-selective inhibitor, designed to inhibit ALK fusions that express the normal ALK kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to first, second, and third generation ALK inhibitors. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
NUVL Price Returns
| 1-mo | -9.18% |
| 3-mo | -22.02% |
| 6-mo | 4.47% |
| 1-year | 15.18% |
| 3-year | 323.43% |
| 5-year | N/A |
| YTD | 14.44% |
| 2023 | 147.11% |
| 2022 | 56.41% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...